Bli medlem
Bli medlem

Du är här


Camurus AB: Camurus to provide an update on the progress of its research and development programs at the Jefferies 2016 Healthcare Conference

Lund - 11 November 2016 - Camurus AB (Nasdaq Stockholm; CAMX) today
announces that Camurus is scheduled to present at the Jefferies 2016
London Healthcare Conference on November 16 at 5:20 pm local time

Fredrik Tiberg, President and CEO, Camurus will provide an update on
the company's development pipeline, including the ongoing Phase 3
program for the weekly and monthly buprenorphine depots (CAM2038) for
treatment of opioid dependence and pain. An update on the strategic
priorities will also be provided, including the building of the
European commercial organization in preparation for the anticipated
launch of CAM2038 for treatment of opioid dependence in 2018.

Camurus has made good progress in accelerating its portfolio in
therapeutic areas of addiction, pain, endocrinology and cancer, with
a recent addition of three new drug candidates in clinical
development. Camurus' clinical stage pipeline comprises 10 programs
developed alone or together with international pharmaceutical and
biotech partners; including Novartis, Braeburn Pharmaceuticals and
Rhythm. Results from a pivotal Phase 3 efficacy study of weekly and
monthly buprenorphine depots for treatment of opioid dependence are
expected during the fourth quarter 2016. An updated development
pipeline table is available at

The audio and slide presentation will be webcasted live and can be
accessed via Camurus web site

About Camurus
Camurus is a Swedish research-based pharmaceutical company committed
to developing and commercializing innovative and differentiated
medicines for the treatment of severe and chronic conditions. New
drug products with best-in-class potential are conceived based on the
proprietary FluidCrystal® drug delivery technologies and an extensive
R&D expertise. Camurus' clinical pipeline includes products for
treatment of cancer, endocrine diseases, pain and addiction,
developed in-house and in collaboration with international
pharmaceutical companies. The company's shares are listed on Nasdaq
Stockholm under the ticker "CAMX". For more information, visit

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92

Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92

The information was submitted for publication at 08.00 a.m. CET on 11
November 2016.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.